[S-24] Potential disease modifying therapies for Parkinson disease

[S-24-4] Cholinesterase inhibitor may improve PD prognosis

Toru Baba (Department of Neurology, Sendai-Nishitaga National Hospital, Japan)

The concept of “disease modification” encompasses intervention types ranging from those designed to slow the underlying degeneration to treatments aiming at compensating lost neuronal functions. It is the ultimate goal of Parkinson disease treatment, although all attempts to develop effective disease-modifying therapy have failed to date. Many reasons have been proposed for these failures including our poor understanding of disease pathogenesis and the lack of sensitive surrogate markers of PD. Moreover, several observations suggest that the PD is not a single disease, but syndrome based on a variety of pathophysiological mechanisms. However, recently several promising new approaches have been reported and attracted attentions. The aim of this symposium is to elucidate true possibilities and real limitations of such novel trials.

Education:
2012 Ph.D., Department of Neurology, Tohoku University Graduate School of Medicine
2003 M.D., Gunma University School of Medicine

Work Experience:
2018 Chief Neurologist, Sendai-Nishitaga National Hospital
2016 Lecturer, Department of Behavioral Neurology & Cognitive Neuroscience, Tohoku University Graduate School of Medicine
2012-2016 Assistant Professor, Department of Behavioral Neurology & Cognitive Neuroscience, Tohoku University Graduate School of Medicine